Use of Endocrine Therapy for Breast Cancer Risk Reduction
Introduction
Introduction
Diagnosis
...gnosis...
...Cancer Risk Assessment ToolsHaving trouble v...
Treatment
...eatmen...
...ble 2. Summary of All Recom...
...moxife...
...hould be discussed as an option to...
Is NOT recommended for use in women with a h...
...s NOT recommended for women who are p...
...NOT recommended in combination with hormone the...
...uld include a timely work-up of abnormal...
...ons with patients and health care provid...
DOSAGE: 20 mg/d orally for 5 years. (EB, S)72...
...idence-based on 5 RCTs with low risk of bias)...
...oxifene...
...ld be discussed as an option to reduce th...
...er than 5 years in women with osteopor...
Should NOT be used for BC risk reduct...
...ded for use in women with a history...
...cussions with patients and health care pro...
DOSAGE: 60 mg/d orally for 5 yea...
...dence-based on 4 RCTs with low risk of bias)...
Exemestane
...uld be discussed as an alternative to...
...T be used for BC risk reduction in premenopausal...
...patients and health care providers sho...
...5 mg/d orally for 5 years. (EB, M)7251
...nce-based on 1 RCT with low risk of bias)...
...nastrozo...
...(1 mg/day orally for 5 years) should...
...omen most likely to benefit are those with...
Clinicians should NOT prescribe anastrozo...
...scussions between patients and health care prov...
...tiating an aromatase inhibitor, clinicians...
...inicians should inform women also of the pos...
...efits outweigh harms; Evidence quality...
...le 3. Summary of Agent IndicationsHa...
Table 4. Adverse Effects of Endocrine TherapyHavin...